Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW; Initiative on Crohn's and Colitis, The Netherlands. van der Woude CJ, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2010 Oct;16(10):1708-16. doi: 10.1002/ibd.21252. Inflamm Bowel Dis. 2010. PMID: 20848453 Clinical Trial.
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE. Reinisch W, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2010 Feb;16(2):233-42. doi: 10.1002/ibd.21038. Inflamm Bowel Dis. 2010. PMID: 19637334 Clinical Trial.
Medical therapy for Crohn's disease strictures.
Van Assche G, Geboes K, Rutgeerts P. Van Assche G, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2004 Jan;10(1):55-60. doi: 10.1097/00054725-200401000-00009. Inflamm Bowel Dis. 2004. PMID: 15058528 Review.
C-reactive protein as a marker for inflammatory bowel disease.
Vermeire S, Van Assche G, Rutgeerts P. Vermeire S, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2004 Sep;10(5):661-5. doi: 10.1097/00054725-200409000-00026. Inflamm Bowel Dis. 2004. PMID: 15472532 Review.
Endoscopic therapy of strictures in Crohn's disease.
Van Assche G, Vermeire S, Rutgeerts P. Van Assche G, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2007 Mar;13(3):356-8; discussion 362-3. doi: 10.1002/ibd.20091. Inflamm Bowel Dis. 2007. PMID: 17230480 Review. No abstract available.
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. D'Haens G, et al. Among authors: rutgeerts p. Lancet. 2008 Feb 23;371(9613):660-667. doi: 10.1016/S0140-6736(08)60304-9. Lancet. 2008. PMID: 18295023 Clinical Trial.
727 results